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Hypothesis.Smallerandlower-volumehospitalscanattainsurgicaloutcomessimilartohigh-volumecentersiftheyincorporatethe
expertise and health care pathways of high-volume centers. Setting. The academic tertiary care center, Moﬃt-Long Hospital (ML);
thecommunity-basedMountZionHospital(ZION);theSanFranciscoCountyGeneralHospital(SFGH);andtheVeteransAﬀairs
MedicalCenterofSanFrancisco(VAMC).Patients.369patientswhounderwentpancreaticoduodenectomybetweenOctober1989
and June 2003 at the University of California, San Francisco (UCSF) aﬃliated hospitals. Interventions. Pancreaticoduodenectomy.
Design. Retrospective chart review. To correct for the potentially confounding eﬀect of small case volumes and event rates, data
for SFGH, VAMC, and ZION was combined (Small Volume Hospital Group; SVHG) and compared against data for ML. Main
Outcome Measures. Complication rates; three-year and ﬁve-year survival rates. Results. The average patient age and health, as de-
termined by ASA score, were similar between ML and the SVHG. The postoperative complication rate did not diﬀer signiﬁcantly
between ML and the SVGH (58.8% versus 63.1%). Patients that experienced a complication averaged 2.5 complications in both
groups. The perioperative mortality rate was 4% for patients undergoing pancreaticoduodenectomy at either ML or the SVGH.
Although the 3-year survival rate for patients with adenocarcinoma of the pancreas was nearly twice as high at ML (31.2% versus
18.3% at SVHG), there was no signiﬁcant diﬀerence in the 5-year survival rates (19% at ML versus 18.3% at SVHG). Conclusions.
Low-volume hospitals can achieve similar outcomes to high-volume tertiary care centers provided they import the expertise and
care pathways necessary for improved results.
Copyright © 2008 Micheal T. Schell et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Pancreaticoduodenectomy is the only potentially curative
treatment for pancreatic cancer, which ranks ﬁfth in cancer-
related mortality worldwide [1–4]. However, because pan-
creatic cancer usually presents late, only 10% to 20% of pa-
tients are candidates for pancreaticoduodenectomy [5, 6], a
potentially lifesaving procedure that is associated with high
morbidity and a disappointing 5-year survival rate of 10% to
29% [7–12].
Evidence showing better outcomes after complex surgi-
c a lp r o c e d u r e ss u c ha sp a n c r e a t i c o d u o d e n e c t o m yi nh i g h -
volume hospitals has led to the suggestion that these proce-
dures are regionalized to high-volume institutions [13–17].
However,althoughbetteroutcomeshavebeenattributedtoa
high volume of pancreaticoduodenectomies speciﬁcally [18–
20], some believe that it is a high volume of complex proce-
dures performed at a high-volume hospital, and not neces-
sarily a speciﬁc procedure itself that is responsible for bet-
ter outcomes [21]. We also believe that it is the high vol-
ume of complex procedures performed at academic tertiary
referral centers that enables them to optimize their opera-
tive and perioperative health care delivery systems to achieve
better outcomes. We, therefore, hypothesized that if the opti-
mized health care delivery systems of high-volume hospitals
were exported to smaller, low-volume hospitals, their out-
comes would approximate those of larger, high-volume hos-
pitals. To examine this hypothesis, we retrospectively ana-
lyzed the surgical and survival outcomes for patients treated
with pancreaticoduodenectomy at the low- and high-volume
hospitals aﬃliated with the University of California, San
Francisco.2 HPB Surgery
2. METHODS
2.1. Datasource
This was a retrospective chart review of 369 patients treated
within the hospitals aﬃliated with the University of Cali-
fornia, San Francisco (UCSF) from October 1989 to June
2003. The hospitals include the academic tertiary care cen-
ter, Moﬃt-Long Hospital (ML, n = 301), which averaged
23 pancreaticoduodenectomies per year; the Veterans Af-
fairs Medical Center of San Francisco (VAMC, n = 41),
which averaged 3 pancreaticoduodenectomies per year; and
the community-based Mount Zion Hospital (ZION, n =
9) and the San Francisco County General Hospital (SFGH,
n = 18), each of which averaged approximately 1 pancre-
aticoduodenectomy per year. Patients were identiﬁed by us-
ing discharge codes for pancreatectomy (52.51, 52.53, 52.6,
52.7) from the International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation (ICD-9), and Current Proce-
dural Terminology (CPT) codes for the Whipple-type proce-
durewithpancreaticojejunostomy(48150)andwithoutpan-
creaticojejunostomy (48152), the pylorus-sparing Whipple-
type procedure with pancreatojejunostomy (48153) and
without pancreatojejunostomy (48154), as well as total pan-
createctomy (48155). Followup data was obtained through
the cancer registry of each institution. At the time of the
study,184patientshaddied,9werelost-to-followup,andthe
remaining176hadbeenmonitoredforanaverageof5.0±3.7
years (mean ± SD). This study was approved by the UCSF
Committee on Human Research and by the individual Insti-
tutional Review Boards at all hospitals where applicable.
2.2. Outcomevariables
Patient demographics and relevant patient history includ-
ing age, sex, date of birth, race, and co-morbidities were
documented. Inpatient variables included the date of proce-
dure, complications, length of stay in the intensive care unit
(ICU) and hospital, and disposition after discharge. We also
recordeddataregardingtheindicationforsurgery,theAmer-
icanSocietyofAnesthesiologists(ASA)riskscore,thetypeof
resection (pylorus- preserving versus classic; distal gastrec-
tomy), the extent of pancreatic resection, whether the supe-
rior mesenteric vein was resected, intraoperative blood loss,
the incidence and number of blood transfusions, and opera-
tivetime.Pathologydataconsistedoftumorsiteoforigin,tu-
mor diﬀerentiation and diameter, resection margins, and ev-
idence of perineural or vascular invasion. Perioperative mor-
tality (deﬁned as death in hospital or within 30 days of dis-
charge) and long-term survival were ascertained for patients
seen at the four hospitals.
2.3. Statisticalanalysis
The Kruskal-Wallis test was used to compare the mean and
median values of continuous data. Fisher’s exact test was
used to evaluate statistical signiﬁcance for categorical data.
Signiﬁcance was set at P ≤ .05. The Kaplan-Meier method
Table 1: Characteristics of patients who underwent pancreatico-
duodenectomy at UCSF-aﬃliated hospitals, 1989–2003.
Characteristics ML LVHG P value†
Age, mean (median), year 61 (64) 62 (62) .887
Sex, no. (%)‡ —— <.0001
Male 153 (50.8) 59 (86.8) —
Race, no. (%)‡ —— <.0001
Asian 33 (11) 7 (10.4) —
African american 8 (2.7) 13 (19.4) —
Hispanic 17 (5.6) 5 (7.5) —
Caucasian 206 (68.4) 37 (55.2) —
Other 37 (12.3) 5 (7.5) —
ASA Rating, no. (%)‡ — — .605
1 4 (1.3) 1 (3.8) —
2 142 (47.8) 12 (46.2) —
3 148 (49.8) 13 (50) —
4 3 (1) 0 (0) —
†According to the Kruskal-Wallis test for continuous data or Fisher’s exact
test for categorical data.
‡Numbers may not sum to group total because data was not available for all
patients.
wasusedtocalculatethree-yearandﬁve-yearsurvivalcurves,
which were compared using the log-rank test. To correct for
the potentially confounding eﬀect of small case volumes and
event rates, data for SFGH, VAMC, and ZION was combined
(LowVolumeHospitalGroup;LVHG)andcomparedagainst
data for ML.
3. RESULTS
The average patient age and health, as determined by ASA
score, were similar, though the sex and race of the patient
populations were signiﬁcantly diﬀerent between ML and the
LVHG (Table 1). Although the most common indication for
surgery at ML (50.2%) and LVHG (51.7%) was pancreatic
cancer (Figure 1), there was signiﬁcant variation between
the groups. Pylorus-preserving procedures were performed
moreoftenthanclassicdistalgastrectomyproceduresbothat
ML (64.7% versus 35.3%) and LVHG (56.1% versus 43.9%)
without a signiﬁcant diﬀerence in the rates (Table 2). Su-
perior mesenteric vein resection was performed in 9% of
patients in both groups. Although average blood loss dif-
fered signiﬁcantly between ML and LVHG, the transfusion
rate and average number of transfused units of blood in pa-
tients requiring transfusion did not. Total operative time and
lengthofstayintheICUandinthehospitalweresigniﬁcantly
shorter at ML than at the LVHG (Table 2).
The postoperative complication rate did not diﬀer sig-
niﬁcantly between ML and the SVHG (58.8% versus 63.1%,
Table 3). The average number of complications per patient,
among those that experienced a complication, was 2.5. Only
cardiopulmonary complications occurred at a signiﬁcantly
diﬀerent rate, and were the most frequent complication in
each group.Micheal T. Schell et al. 3
Table 2: Operative and perioperative characteristics of patients who underwent pancreaticoduodenectomy at UCSF-aﬃliated hospitals,
1989–2003.
Characteristics ML LVHG P value†
Procedure type, no. (%) — — .206
Pylorus-preserving 194 (64.7) 37 (56.1) —
Classic; distal gastrectomy 106 (35.3) 29 (43.9) —
Vein resection, no. (%) — — 1.000
No. 274/301 (91) 52/57 (91.2) —
Blood loss, mean (SD), ml 1166.7 (1410.7) 1262.7 (836.7) .012
Patients receiving a transfusion, no. (%) 134/301 (44.5) 29/53 (54.7) .1813
Units transfused, mean (SD) 3.3 (3.9) 2.6 (1.3) .930
Operative time, mean (SD), h 6.7 (2) 8.3 (2.1) <.0001
ICU stay, mean (SD), days 2.1 (7) 8.8 (21.6) <.0001
Post-Op hospital stay, mean (SD), days 16.1 (23.5) 24.5 (24) <.0001
†According to the Kruskal-Wallis test for continuous data or Fisher’s exact test for categorical data.
Table 3: Complications in patients who underwent pancreaticoduodenectomy at UCSF-aﬃliated hospitals, 1989–2003.
Complications ML (n = 301) LVHG (n = 68) P value†
Complication, no. (%) 177 (58.8) 41 (60.3) .579
Complications per patient, mean (SD) 2.5 (2.6) 2.5 (1.8) .221
General types of complications, no. (%) — — —
Cardiopulmonary 52 (17.3) 20 (29.4) .028
Wound 41 (13.6) 10 (14.7) .846
Pancreatic leak or ﬁstula 38 (12.6) 4 (5.9) .140
Secondary procedures 23 (7.6) 8 (11.8) .330
Postoperative hemorrhage 19 (6.3) 3 (4.4) .778
Enteric leak, ﬁstula, or stricture 10 (3.3) 1 (1.5) .697
Delayed gastric emptying 14 (4.7) 4 (5.9) .754
Reoperation 22 (7.3) 8 (11.8) .224
†According to Fisher’s exact test for categorical data.
The pancreas was the most common site of tumor origin
in both groups (Figure 2). Tumor pathology was similar in
both groups; adenocarcinoma accounted for approximately
67–69% of the cases (Figure 3). The average tumor diame-
ter, the incidence of positive margins, and the percentages
and patterns of patients with a low, moderate, or high grade
of tumor diﬀerentiation did not diﬀer signiﬁcantly between
LVHG and ML, but neural invasion did (Table 4).
The perioperative mortality rate for patients undergoing
pancreaticoduodenectomy was approximately 4% in both
groups(notshown).Althoughthe3-yearsurvivalrateforpa-
tients with adenocarcinoma of the pancreas was nearly twice
ashighatML(31.2%versus18.3%atLVHG,Figure 4),there
wasnosigniﬁcantdiﬀerenceinthe5-yearsurvivalrates(19%
at ML versus 18.3% at LVHG).
4. DISCUSSION
Our results demonstrate that morbidity and mortality out-
comes were consistent between the low-volume and high-
volume hospitals aﬃliated with UCSF. We believe that this
is due to the sharing of operative techniques and periop-
erative care pathways, which has enabled the low-volume
hospitals to develop a health care delivery system that re-
sembles the large-volume hospital and achieves comparable
results.
The low-volume hospital group, which consisted of a
community-based hospital and a county general hospital,
eachofwhichaveraged1pancreaticoduodenectomyperyear,
andaVeteransAﬀairsMedicalCenterthataveraged3pancre-
aticodudenectomies per year, was able to minimize adverse
events to the same extent as the large-volume tertiary cen-
ter, which averaged 23 pancreaticodudenectomies per year.
The hospitals did not diﬀer signiﬁcantly in the percentage
of patients experiencing a complication. In fact, the mean
and median numbers of complications among patients who
had a complication were exactly the same. Moreover, the
pancreatic ﬁstulas and anastomotic leaks that are often as-
sociated with longer hospitalizations and increased mortal-
ity occurred at statistically equivalent lower rates (12.6 %
at ML and 5.9% in the LVHG) than the internationally re-
ported average of 14.3%–26.7% [23]. Uniform patient selec-
tion among the hospitals likely aided in the eventual similar
outcomes,becausealthoughracialandgenderdiﬀerencesex-
isted between the LVHG and ML, the general health and age
of the patients were similar.4 HPB Surgery
Table 4: Pathologic diagnosis in patients who underwent pancreaticoduodenectomy at UCSF-aﬃliated hospitals, 1989–2003.
Characteristics ML LVHG P value†
Tumor diameter, mean (SD), cm 3.0 (1.5) 2.9 (1.7) 1.000
Tumor diﬀerentiation, no. (%)‡ — — .575
Low 36 (39.1) 7 (30.4) —
Moderate 46 (50) 12 (52.2) —
High 10 (10.9) 4 (17.4) —
Positive tumor margins, no. (%) 25 (26.9) 6 (25) 1.000
Positive vascular invasion, no. (%) 28 (31.1) 7 (58.3) .102
Positive neural invasion, no. (%) 54 (60) 14 (87.5) .047
†According to the Kruskal-Wallis test for continuous data or Fisher’s exact test for categorical data.
‡Numbers may not sum to group total because data was not available for all patients.
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Figure 1: Indication for pancreaticoduodenectomy at UCSF-
aﬃliated hospitals, 1989–2003. ML, Moﬃt-Long Hospital; LVHG,
low-volume hospital group, is the combined data for San Francisco
County General Hospital, Veterans Aﬀairs Medical Center of San
Francisco, and Mount Zion Hospital (P = .003 by Fisher’s exact
test).
Clinic notes and information obtained through the ap-
propriate cancer registries showed a median followup of 5.0
and 5.9 years at ML and the LVHG, respectively. Although
there are inherent limitations to a retrospective chart re-
view, we believe that the prolonged followup period allows
us to accurately ascertain the long-term survival through
our methods. For all patients who underwent pancreatico-
duodenectomy for any indication, perioperative mortality
and ﬁve-year survival did not diﬀer signiﬁcantly between
the SVGH and ML. In addition, for patients who underwent
pancreaticoduodenectomy for adenocarcinoma of the pan-
creas either at the LVHG or ML, the perioperative mortal-
ity and ﬁve-year survival rates were similar and compara-
ble to the nationally reported rates of 3%–11% and 10%–
29%, respectively [7–12, 22]. However, in our study, as in
others, there was a signiﬁcant diﬀerence between the low-
and high-volume hospitals in the three-year survival rate
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Figure 2: Pathological tumor site for patients undergoing pancre-
aticoduodenectomy at UCSF-aﬃliated hospitals, 1989–2003. ML,
Moﬃt-Long Hospital; LVHG, low-volume hospital group, is the
combined data for San Francisco County General Hospital, Veter-
ans Aﬀairs Medical Center of San Francisco, and Mount Zion Hos-
pital (P = .201 by Fisher’s exact test).
for patients treated with pancreaticoduodenectomy for ade-
nocarcinoma of the pancreas [1–4]. Further investigation
into postoperative care pathways and procedural capabilities
that may account for the early disparity in survival is clearly
warranted.
Theaverageoperative timeintheLVHGwassigniﬁcantly
longer than at ML, as was the average blood loss (although
onlyby96cc).Theclinicalimportanceofanadditionalblood
loss of 96cc is pedagogical at best, and is further diminished
by our ﬁnding that the percentage of patients requiring a
transfusion and the average number of units transfused in
such patients were similar among the groups. The diﬀerence
in operative time may reﬂect the advantage that a high vol-
ume of cases gives a surgical team in terms of operative ef-
ﬁciency. However, since the rate and number of units trans-
fused, the perioperative mortality, the rate and average num-
ber of complications, and the 5-year survival rates were notMicheal T. Schell et al. 5
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Figure 3: Pathological tumor type for patients undergoing pancre-
aticoduodenectomy at UCSF-aﬃliated hospitals, 1989–2003. ML,
Moﬃt-Long Hospital; LVHG, low-volume hospital group, is the
combined data for San Francisco County General Hospital, Veter-
ans Aﬀairs Medical Center of San Francisco, and Mount Zion Hos-
pital; IPMN, Intraductal Papillary Mucinous Neoplasm (P = .202
by Fisher’s exact test).
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Figure 4: Comparison of Kaplan-Meier survival curves for pa-
tients with adenocarcinoma of the pancreas. The survival data from
Mount Zion hospital, San Francisco General County hospital, and
the Veterans Aﬀairs Medical Center were combined (LVHG) and
compared with data from Moﬃtt-Long Hospital (ML). (P = .035 at
3 years; P = .096 at 5 years, by Log-Rank test).
signiﬁcantly diﬀerent between the LVHG and ML, operative
eﬃciency did not seem to aﬀect eﬃcacy.
The greater eﬃciency in the health care system at ML
was also reﬂected in the signiﬁcantly shorter stays in both
the ICU and the hospital. Although we cannot establish a
causal relationship, we believe the longer hospital stays in the
LVHGweremostlikelyinﬂuencedbytheextendedICUstays.
Perhaps the inability of the LVHG to provide the necessary
care and observation outside the ICU was a factor in the in-
creasedlengthof stay,butfurtherstudiesareneeded toassess
whether there is a signiﬁcant disparity between the technical
capabilities of the LVHG and ML. More importantly, if there
are important diﬀerences in staﬀ or resource capabilities that
could be identiﬁed and corrected, perhaps the LVHG, as well
as other small and low-volume hospitals, could achieve ICU
and hospital stays which approximate those of high-volume
hospitals.
Optimal long-term surgical outcomes were achieved at
the hospitals aﬃliated with UCSF. For several reasons we be-
lieve that these outcomes indicate that health care delivery
systems similar to ours can produce comparable results, in-
dependentofthevolumeofpancreaticoduodenectomiesper-
formed. First, UCSF residents rotate through all the aﬃliated
hospitals and may transmit or share knowledge gained at the
tertiary care center (ML) on how to preoperatively evalu-
ate patients, assist at and perform a pancreaticoduodenec-
tomy, and recognize potential postoperative complications.
Secondly, the aﬃliated hospitals all participate in the UCSF
morbidity and mortality education system, which serves to
enlighten the surgeons and the ancillary services such as
anesthesia, interventional radiology, and nursing. Lastly, ex-
pert surgeons and case-related specialists often travel be-
tween hospitals to aid in preoperative assessment and the
technical aspects of the cases. We consider the low-volume
hospitals to be independent institutions that are capable of
importing the critical elements of a successful health care de-
livery system in order to increase the health care options of
patients in their surrounding communities. Perhaps the best
way to improve access to and the outcomes of complex sur-
gical procedures for the majority of the population in the
United States is to develop speciﬁc programs in selected low-
volume centers that would be aﬃliated with, modeled after,
and thus eﬀectively emulate the practices and processes ev-
ident in high-volume hospitals. Despite the intuitive appeal
of regionalizing the performance of complex surgical proce-
dures,thereareseveralbarriers,includingpatientpreference,
that limit the practical utility of this approach. Still, one can-
not overemphasize the essential importance of low volume
hospitals implementing detailed, comprehensive programs
in order to safely provide high-quality, complex surgical ser-
vices. By identifying, exporting, and implementing the op-
erative decision making and perioperative care pathways that
enablehigh-volumecenterstoachieveconsistentlygoodout-
comes into small and low-volume hospitals, their outcomes
should approximate those of the high-volume centers. We
areencouragedbyourearlyexperiencesachieving justsucha
goal in a local, county medical center in Northern California
[22].
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